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Abstract
Background: Understanding shedding patterns of 2009 pandemic influenza A (H1N1) (pH1N1) can inform recommenda-
tions about infection control measures. We evaluated the duration of pH1N1 virus shedding in patients in Nairobi, Kenya.
Methods: Nasopharyngeal (NP) and oropharyngeal (OP) specimens were collected from consenting laboratory-confirmed
pH1N1 cases every 2 days during October 14–November 25, 2009, and tested at the Centers for Diseases Control and
Prevention-Kenya by real time reverse transcriptase polymerase chain reaction (rRT-PCR). A subset of rRT-PCR-positive
samples was cultured.
Results: Of 285 NP/OP specimens from patients with acute respiratory illness, 140 (49%) tested positive for pH1N1 by rRT-
PCR; 106 (76%) patients consented and were enrolled. The median age was 6 years (Range: 4 months–41 years); only two
patients, both asthmatic, received oseltamivir. The median duration of pH1N1 detection after illness onset was 8 days (95%
CI: 7–10 days) for rRT-PCR and 3 days (Range: 0–13 days) for viral isolation. Viable pH1N1 virus was isolated from 132/162
(81%) of rRT-PCR-positive specimens, which included 118/125 (94%) rRT-PCR-positive specimens collected on day 0–7 after
symptoms onset. Viral RNA was detectable in 18 (17%) and virus isolated in 7/18 (39%) of specimens collected from patients
after all their symptoms had resolved.
Conclusions: In this cohort, pH1N1 was detected by rRT-PCR for a median of 8 days. There was a strong correlation between
rRT-PCR results and virus isolation in the first week of illness. In some patients, pH1N1 virus was detectable after all their
symptoms had resolved.
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Introduction
The 2009 pandemic influenza A (H1N1) (pH1N1) virus has
been circulating worldwide since the initial cases were detected in
the United States in April 2009 [1]. In order to control the spread
of infection, public health agencies including the World Health
Organization (WHO) and the United States Centers for Disease
Control and Prevention (CDC) made recommendations on the
duration of isolation of pH1N1 cases. The recommendations were
based on previous knowledge about duration of shedding of
seasonal influenza viruses [2,3,4]. Most patients infected with
seasonal influenza shed the virus for 5–7 days. However, children
have been shown to shed the virus for up to 21 days and severely
immunocompromised individuals up to several months [2,5].
Following the onset of the influenza pandemic in 2009, WHO
recommended that control precautions such as self-isolation
should be practiced for 7 days from symptom onset or until all
symptoms resolve [6].
Much of the information on pH1N1 virus shedding is from
studies conducted in North America, Asia, and Europe
[7,8,9,10,11,12]. In many of these studies, real time reverse
transcriptase polymerase chain reaction (rRT-PCR) positive
results were used to identity positive cases and determine the
duration of virus shedding. A study in Hong Kong found that
pH1N1 virus RNA was shed from the respiratory tract for up to 8
days (median=4 days) after symptom onset, [10]. Studies carried
out in China and Germany showed that pH1N1-infected patients
shed the virus for a mean of 6 days (Range: 1–17) and 6.6 days
(Standard deviation: 2.6), respectively [10,11]. In addition, a case
report from the United States reported that pH1N1 virus was
detected in respiratory samples 5 to 6 weeks after initial diagnosis
in 2 severely immunocompromised patients on chemotherapy;
these patients were on oseltamivir treatment and developed
resistance to the drug [9].
The first case of pH1N1 in Kenya was detected in June 2009
[13]. At that time, the Kenya Ministry of Public Health and
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20320Sanitation followed WHO guidelines and recommended 7 days of
self-isolation for all pH1N1 patients. In order to assist in providing
evidence-based recommendations for infection control, we tested
serial specimens from laboratory-confirmed pH1N1 patients
attending a clinic in Nairobi to determine the duration of viral
shedding, determine the correlation between rRT-PCR-positive
results and viral isolation, and evaluate clinical signs and
symptoms associated with shedding.
Materials and Methods
Ethics Statement
This study was approved by both the Institutional Review
Board of CDC-Atlanta and the Ethical Review Committee of the
Kenya Medical Research Institute (KEMRI).
Consent
Informed written consent was obtained from all participants.
For children, written consent was obtained from parents or
guardians.
Setting and Study Design
We conducted the study in a large informal urban settlement in
Nairobi, in an existing population-based surveillance system that
has been previously described [14]. Consenting participants who
presented to a field clinic, known as Tabitha Clinic, within the
surveillance site with signs and symptoms consistent with
influenza-like illness (ILI) or severe acute respiratory illness (SARI)
had oropharyngeal (OP) and nasopharyngeal (NP) specimens
taken. The specimens were tested for influenza by rRT-PCR at the
KEMRI/CDC-K laboratory in Nairobi.
An ILI case was defined as a patient with fever $38uC and
cough or sore throat for all ages. For SARI, the definitions varied
by age group. In children ,5 years old, SARI was defined as
cough or difficulty breathing along with a danger sign; unable to
drink or breast feed, lethargic or unconscious, vomiting every-
thing, convulsions, nasal flaring, grunts, chest indrawing, stridor in
a calm child or oxygen saturation #90%. In people $5 years,
SARI was defined as fever $38uC plus cough or shortness of
breath or chest pain or oxygen saturation #90%.
Patients who came to Tabitha Clinic between October 14,
2009, and November 25, 2009, who had ILI or SARI and NP/OP
specimens that tested positive for pH1N1 were recruited for the
study. Patients who were positive for pH1N1 were contacted at
their homes by field workers and requested to return to the clinic
for follow up every 2 days. During the initial visit and subsequent
visits, a trained clinician recorded signs and symptoms and
collected both NP and OP specimens. Patients who had 2
consecutive rRT-PCR negative specimens were released from the
study. A patient was considered to have pH1N1 RNA if a
specimen collected on that day was positive for pH1N1 by rRT-
PCR. Patients were not followed over the weekend.
Specimen collection and laboratory testing
Specimens were obtained according to the following procedure:
for OP specimens, a sterile nylon-tipped plastic-shafted OP swab
touched the back of the oropharyngeal mucosal membrane for
3–5 seconds and then was placed into a cryovial containing 1 mL
of viral transport media (VTM). VTM was prepared at the
KEMRI/ CDC-K laboratory using the standard WHO protocol
that includes bovine serum albumin and veal infusion broth
supplemented with amphotericin B (www.who.int/csr/resources/
publications/surveillance/Annex8.pdf). Freshly preparedrefrigerated
V T Mw a su s e df o ru pt o3m o n t h s .F o rN Ps p e c i m e n s ,ap o l y e s t e r -
tipped flexible aluminum-shafted NP swab was inserted into the
nose to the nasopharynx, where it was rotated 180 degrees and
left in place for 3–5 seconds. The NP swab was inserted into the
cryovial containing the OP swab from the same patient. The
specimens were labeled and transported at 4uC to the KEMRI/
CDC-K laboratory where they were tested for influenza A and
pH1N1 using rRT-PCR within 24 hours.
The rRT-PCR testing was performed using the CDC pH1N1
testing protocol [15]. Briefly, total RNA was extracted from
100 mL aliquots of each specimen using QIAamp viral RNA
minikit (Qiagen Inc., GmbH, Germany) according to the
manufacturer’s instructions. One step rRT-PCR was carried out
using the AgPath kit (Applied Biosystems, California, USA). For
influenza A detection, the primers used were 59GAC CRA TCC
TGT CAC CTC TGA C as the forward, and 59 TG CAG TCC
TCG CTC ACT GGG CAC G as the reverse. The influenza A
detection probe was 59 TGC AGT CCT CGC TCA CTG GGC
ACG. For pH1N1, we used the 59GTG CTA TAA ACA CCA
GCC TYC CA as the forward primer, 59 CGG GAT ATT CCT
TAA TCC TGT RGC as the reverse primer, and 59CA GAA
TAT ACA TCC RGT CAC AAT TGG ARA A as the probe.
Specimens were also tested for seasonal influenza A H1 and H3.
Following the reverse transcription step, a typical 45 cycle PCR
reaction was run and fluorescence was read at the annealing/
extension step. Appropriate negative and positive control speci-
mens were run alongside each reaction. The results were recorded
as cross-over threshold (CT) values. Any influenza A CT value
,40.0 was recorded as positive; CT value 40.0–44 were
considered indeterminate, and those without a CT reading were
recorded as negative. A specimen was considered to be pH1N1
positive if both the influenza A and the pH1N1 CT values were
,40.0 as described in the CDC protocol of real time RT-PCR for
influenza A(H1N1) [16].
Later, in order to evaluate the concordance between rRT-PCR
testing and viral culture for pH1N1, influenza virus isolation in
Mardin-Darby Canine Kidney (MDCK) cells was attempted for
the first rRT-PCR-positive specimen, the last rRT-PCR-positive
specimen, and the first rRT-PCR-negative specimen from each
enrolled patient. Confluent monolayers of MDCK cell line
growing in T25 cell culture flasks were used. Media were removed
from the flasks. Each flask was inoculated with 100 mL of specimen
and inoculum was allowed to adsorb on the cells for 30 min at
37uC. Following adsorption, 6 mL of Viral Growth Medium
[DMEM supplemented with HEPES buffer, bovine serum
albumin, L-Glutamine, trypsin, and antibiotic-antimycotic (Sig-
ma-Aldrich, Inc., St. Louis, MO, USA)] was added and cultures
were observed daily for cytopathic effect (CPE) for up to 6 days, at
which point all the cultures were harvested. Cultures that showed
observable CPE by microscopy were subjected to hemagglutina-
tion assay using guinea pig red blood cells. Supernatants from
cultures that showed no CPE were subjected to a second passage,
following which cultures with observable CPE were subjected to
hemagglutination assay. Cultures that had no observable CPE
after the second passage were considered negative by viral
isolation.
Data collection and statistical methods
Data were collected in three ways. First, information related to
the patient’s initial visit was recorded on computers by clinicians at
Tabitha Clinic. Second, during the first follow-up clinic visit and
subsequent visits, information about signs and symptoms was
recorded on paper questionnaires and entered into a Microsoft
Access database. The signs and symptoms recorded were fever,
temperature $38uC, cough, sneezing, runny nose, vomiting,
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addition, the following symptoms were recorded for patients $5
years; earache, sore throat, headache, chills, muscle pain, and
abdominal pain. Third, laboratory data were recorded into
Freezerworks software (Dataworks Development, Inc.). Data were
combined into a central database for analysis.
We considered the date of onset of illness to be the date on
which the patient reported the first symptom associated with the
illness, according to the history taken during the patient’s initial
clinic visit. For possible initial symptoms, we considered fever,
cough, and difficulty breathing for patients ,5 years old. In
patients $5 years old, these symptoms and sore throat were
considered as possible initial symptoms. Patients were considered
to have no detectable virus RNA once they had two consecutive
specimens that tested negative for pH1N1 by rRT-PCR. We
defined the last day of virus detection as the midpoint between the
dates of collection of the last rRT-PCR pH1N1-positive specimen
and the first rRT-PCR pH1N1-negative specimen. We were
unable to follow all patients until they had two negative rRT-PCR
tests because some did not return to the clinic for the necessary
follow-up visits. The time to cessation of pH1N1 virus detection
for these patients was right censored at their last pH1N1 rRT-
PCR-positive test date. Thus, the duration of pH1N1 virus
detection for these patients was only known to occur after their
drop out time and was treated accordingly in the survival analysis
below.
Comparisons of duration of pH1N1 virus detection between
groups, described by the median and mean, were conducted using
the log-rank test. A multivariable Cox regression model was used
to determine the association between gender and age with
duration of pH1N1 virus detection. A Kaplan-Meier plot was
used to determine duration of pH1N1 virus detection. Odds ratios
were calculated to determine the odds of isolating pH1N1 virus
from rRT-PCR-positive specimens collected over time. All
analyses were conducted with SAS version 9.1. Findings were
considered statistically significant if the resulting p-value was
,0.05.
Results
A total of 481 patients with respiratory illness were seen at
Tabitha Clinic between October 14, 2009 and November 25,
2009; 175 (36%) had ILI and 306 (64%) had SARI. Specimens
were collected from 285 (59%) of these patients, and 140 (49%) of
these were positive for pH1N1 by rRT-PCR. Of the 140 pH1N1-
positive patients, 106 (76%) consented to participate in the study;
85 (80%) completed the study (Figure 1). Data from all the 106
patients who enrolled in the study were included in the analysis.
The median age of the study population was 6 years (Range: 4
months–41 years); 60 (57%) were females (Table 1). The mean
duration between symptom onset and initial clinic visit was 3 days
(Range: 0–9 days). Four pH1N1-positive patients had underlying
medical conditions: Out of 16 patients who were tested for HIV, 2
were HIV-positive. Two patients had asthma (Table 1) and were
the only enrolled patients who received oseltamivir treatment.
None of the enrolled patients required hospitalization.
Pandemic H1N1 virus detection
From the 106 patients enrolled to the study, 449 specimens were
collected including the initial specimen from which pH1N1 was
detected; 200 (44%) were positive for pH1N1 by rRT-PCR. Virus
isolation was attempted in 262 of the 449 (58%) specimens
collected. The specimens cultured included the 106 initial rRT-
PCR-positive specimens, 56 final rRT-PCR-positive specimens
(fifty patients had only one rRT-PCR-positive specimen), and100
first rRT-PCR-negative specimens from the enrolled patients. No
rRT-PCR-negative specimens were obtained from 6 of the
patients. Of the 162 rRT-PCR-positive specimens, pH1N1 virus
was isolated from 132 (81%) specimens. Of rRT-PCR-positive
specimens taken on day 0–3 after illness onset, 81/85 (95%) were
culture-positive, as were 37/40 (93%) taken on day 4–7, 11/20
(55%) taken on day 8–10, and 3/17 (18%) taken $11 days after
illness onset (Figure 2). Viral isolation was successful in 100/106
(94%) of the rRT-PCR positive specimens collected at the initial
clinic visit. Viral isolation was equally successful in samples with
CT values,25 and those with CT values 25–30 (92% vs. 84%
p=0.25), but more successful for samples with CT values,25
compared to those with CT values 30–39 (92% vs. 63%,
p=0.009). Real time RT-PCR-positive specimens collected from
Figure 1. Flow chart outlining enrollment in the pH1N1 viral
shedding study undertaken in Kenya from Oct 14–Nov 25,
2009.
doi:10.1371/journal.pone.0020320.g001
Table 1. Demographic characteristics of 285 patients with
acute respiratory illness who presented to Kibera Clinic,
Nairobi, Kenya and had specimens collected, Oct–Nov 2009.
Characteristics rRT-PCR Results
Age in years
pH1N1-positive
N( % )
pH1N1-negative
N( % )
,5 43 (40) 90(62)
5–14 41 (39) 32(22)
$15 22 (21) 23(16)
Gender
Male 46(43) 71(49)
Female 60(57) 74(51)
Co-existing medical conditions
HIV 2(13)* 3(14)
Asthma 2 (2) 0
Treated with oseltamivir 2(2) N/A
*16 people were tested for HIV.
doi:10.1371/journal.pone.0020320.t001
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be culture-positive than rRT-PCR-positive specimens collected on
day 4–7 (CI: 1.4–38.9; P,0.012), 17.6 times more likely to be
culture-positive than rRT-PCR-positive specimens collected on
day 8–10 (CI: 3.2–96.1; p,0.001), and 142.9 times more likely to
be culture-positive than specimens collected from patients $11
days after illness onset (CI: 2.4–833.3; P,0.001). Of the 100 rRT-
PCR negative specimens, 6(6.4%) were culture-positive.
The median number of days pH1N1 virus RNA was detectable
in patients specimens 8 days (95% CI: 7–10 days) after symptom
onset. There was no statistically significant difference in the
duration of pH1N1 virus detection between children ,5 years old
and those 5 to 14 years or persons $15 years. There was no
difference in the median duration of pH1N1 virus detection
between males and females. In the majority (58%) of patients,
pH1N1 virus RNA was detected for $7 days, and in 16% of
patients for $14 days (Figure 3). In general, the mean CT value
increased with time. One of the HIV-positive patients who was on
antiretroviral therapy and had a CD4 count of 17cells/mm
3 had
detectable pH1N1 virus RNA for 4 days after symptom onset. The
other HIV-positive patient, who was not on antiretroviral
treatment and whose CD4 count was unknown, had detectable
pH1N1 RNA for 16 days after symptom onset. These two patients
completed the study with two consecutive pH1N1-negative
specimens.
Association between pH1N1 virus detection and clinical
symptoms
There were 200 patient visits that were associated with pH1N1-
positive rRT-PCR results. We were able to link laboratory results
with clinic visit data on symptoms for 186/200 patients. From the
linkable patient visits, there were 69/186 pH1N1-positive rRT-
PCR results from patients ,5 years old and 117/186 from
patients $5 years old. The most common signs and symptoms in
the pH1N1-positive patients ,5 years old were cough [52/69
(75%)], runny nose [47/69 (68%)], reported fever [44/69 (64%)],
and temperature $38uC [40/69 (58%)]. The most common signs
and symptoms in the patients $5 years old were cough [83/117
(71%)], temperature $38uC [63/117 (54%)], reported fever [61/
117 (52%)], and runny nose [60/117 (51%)] (Table 2).
Eighteen (17%) pH1N1 enrolled patients who were initially
symptomatic and pH1N1-positive continued to be rRT-PCR-
positive after all of their signs and symptoms had resolved for a
median of 9 days (interquartile range 7–10 days) after all signs and
symptoms had resolved. Viable pH1N1 virus was isolated from
specimens obtained from 7/18(39%) of these patients.
Figure 2. Correlation between rRT-PCR-positive results, cell culture results, and days of illness.
doi:10.1371/journal.pone.0020320.g002
Figure 3. Kaplan Meier plot showing the probability of rRT-
PCR-positive pH1N1 test result by day after symptom onset.
doi:10.1371/journal.pone.0020320.g003
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This study describes the duration of pH1N1 virus RNA
detection, the correlation between rRT-PCR-positive results and
virus isolation, and clinical symptoms associated with pH1N1 virus
detection in patients living in a densely populated community with
low socioeconomic status in sub-Saharan Africa. Pandemic H1N1
RNA was detected from respiratory specimens by rRT-PCR for a
median duration of 8 days but up to 17 days after symptoms onset.
This duration of virus RNA detection is similar to the median of 6
and 8 days reported in studies from China and Hong Kong,
respectively [7,10]. In our study, we did not find any differences in
the duration of pH1N1 RNA detection among various age groups
or between males and females. These results were similar to those
reported by a study in Hong Kong, which reported no correlation
between influenza viral load and age [17], and one from Canada
which showed no differences in shedding between children and
adults [8]. In contrast, studies in Hong Kong and China found
that younger age and male gender were risk factors for prolonged
pH1N1 virus detection [7,10]. Our study population, was mostly
children (79% of the patients were ,14 years old), thus
associations between age and duration of pH1N1 RNA virus
detection were difficult to assess. In addition, our study population
included outpatients only, the China and Hong Kong studies
mentioned above included hospitalized patients [7,10].
Cough, fever, and runny nose were the most common clinical
symptoms associated with pH1N1 virus RNA detection. This is
similar to studies carried out in Korea [18] and Hong Kong [10].
While sore throat was commonly associated with pH1N1 patients
in other studies [1,10,19], in our study, only 29% of the pH1N1-
positive patient visits from patients $5 years old were associated
with this symptom. In our study, a substantial proportion of
patients continued to shed the virus after respiratory symptoms
had resolved. Viable pH1N1 virus, which was potentially
infectious, was isolated from one-third of specimens obtained
from recovered patients. Therefore, some pH1N1 patients who
were no longer symptomatic may still be shedding viable pH1N1
virus. In addition, half of rRT-PCR-positive samples from patients
who were on day 8 to day 10 after symptom onset were culture-
positive. In 2009, in the early stages of the H1N1 pandemic,
WHO recommended that pH1N1 patients remain isolated for 7
days or until symptoms resolved [20]. While these guidelines may
be appropriate for the community, in a healthcare setting, where
the goal is to prevent as much spread as possible, other measures
need to be considered [21].
Of the 2 HIV-positive patients in the study, the patient who was
not on antiretroviral therapy (ART) had detectable pH1N1 virus
RNA for 16 days, much longer than the median duration for the
study population. This is slightly longer than was shown in a study
of HIV-positive school-aged children carried out in Germany in
which the median time from symptoms onset to first negative rRT-
PCR result was 9 days (Range, 5–14 days) and cultures become
negative after 6 days (Range 3–11 days) [22]. Other studies have
shown that immunosuppressed individuals may shed influenza
virus longer than the general population [2,9,19]. In a case report
from the United States of America, 2 cancer patients who were
severely immunosuppressed were shown to continue having
detectable pH1N1 virus RNA for 5 and 6 weeks after initial
diagnosis [9]. In previous studies, severely immunocompromised
patients have been shown to shed seasonal influenza for weeks to
months [2]. The issue of prolonged shedding in immunocompro-
mised patients is especially relevant in sub-Saharan Africa, where
over 22 million people are infected with HIV and only 30% are on
ART [23,24]. In Kenya, the HIV prevalence in persons aged 15–
64 is 7.1% [25], and in the study site, HIV prevalence is 14%
(KEMRI/CDC-K, unpublished data). In our study, we identified
Table 2. Signs and Symptoms associated with pH1N1 rRT-PCR-positive test results.
Patients ,5 yrs Patients $5y r s
Days after symptom onset Days after symptom onset
Symptom
*N 0–3 4–7 8–11 12–20
*N 0–3 4–7 8–11 12–20
Total Patient visits 69 36 15 14 4 117 50 29 19 19
Reported Fever (%) 44(64) 35(97) 7(47) 2(14) 0(0) 61(52) 45(90) 16(55) 0(0) 0(0)
Temp ($38) (%) 40(58) 34(94) 6(40) 0(0) 0(0) 63(54) 49(98) 14(48) 0(0) 0(0)
Cough (%) 52(75) 33(92) 12(80) 5(36) 1(25) 83(71) 45(90) 23(79) 9(47) 6(32)
Sneezing (%) 24(35) 19(53) 4(27) 1(7) 0(0) 31(18) 20(40) 9(31) 2(11) 0(0)
Runny nose (%) 47(68) 31(86) 8(53) 6(43) 2(50) 60(51) 32(64) 17(59) 7(37) 4(22)
Vomiting (%) 17(25) 13(36) 3(20) 1(7) 0(0) 9(8) 6(12) 3(10) 0(0) 0(0)
Diarrhea (%) 8(12) 6(17) 2(13) 2(14) 0(0) 5(4) 2(4) 1(3) 1(5) 1(5)
Chest pain (%) 0(0) 0(0) 0(0) 0(0) 0(0) 23(20) 13(26) 7(24) 3(16) 0(0)
Difficulty Breathing (%) 6(9) 4(11) 2(13) 2(14) 0(0) 7(6) 4(8) 1(3) 2(11) 0(0)
Ear problem (%)* 6(5) 5(10) 0(0) 1(5) 0(0)
Sore throat (%)* 34(29) 22(44) 8(28) 3(16) 1(5)
Headache* 48(41) 30(60) 15(52) 2(11) 1(5)
Chills* 22(19) 14(28) 7(24) 1(5) 0(0)
Joint pain* 15(13) 8(16) 6(21) 1(5) 0(0)
Muscle pain* 10(9) 4(8) 5(17) 1(5) 0(00
Abdominal pain* 8(7) 5(10) 2(7) 1(5) 0(0)
*This information was not obtained from patients ,5 years old.
doi:10.1371/journal.pone.0020320.t002
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prolonged shedding. More research should be conducted to better
understand the extent of pH1N1 viral shedding in untreated HIV-
infected patients and those on ART therapy.
PCR, which detects viral nucleic acid instead of infectious viral
particles, is more sensitive than virus culture in detecting influenza
[26]. However, because it does not detect viable whole virus,
people who have respiratory specimens that are rRT-PCR-positive
may not harbor a sufficient amount of viable virus to infect other
people. The relationship between virus titers and influenza
transmissibility is not known. However, serial interval studies
suggest that most seasonal influenza household transmission occurs
in the first 3 days after the index case’s illness onset [21]. In our
study, we successfully isolated pH1N1 virus from 95% (81/85) of
rRT-PCR-positive specimens taken from day 0–3 after symptom
onset, but only 18% (3/17) rRT-PCR-positive specimens taken
$11 days after symptom onset were culture-positive. These
findings suggest that if a patient has a respiratory specimen taken
early in the course of illness that is positive for pH1N1 by rRT-
PCR, that patient is likely shedding live virus. In contrast, a rRT-
PCR-positive result from a sample taken later in a patient’s course
of illness may not mean that the patient is still shedding live virus.
Our study had some limitations. First, our study population was
mainly comprised of persons ,14 years, and the oldest patient was
41 years old. Thus, we were not able to evaluate viral shedding
patterns in elderly individuals. Second, since few people in our
study had known underlying medical conditions, we were not able
to determine the impact of co-morbidities, including HIV
infection, on duration of pH1N1 viral shedding. Some patients
whose HIV status was unknown may have been HIV-positive; this
could explain the slightly longer duration of rRT-PCR positive
pH1N1 results in our study compared to other studies. Third,
there was an overlap between the patients who presented with ILI
and SARI, thus it was difficult to analyze data for each of the
syndromes separately. Finally, 20% of patients enrolled in the
study did not fully complete the study. Therefore, we have little
information on these patients regarding shedding. We used right-
censoring in our analysis for these patients. These results were
comparable to those obtained from the 85 patients who completed
the study.
In this study, we show that pH1N1 shedding patterns in an
impoverished, densely populated urban community in Nairobi,
Kenya, are similar to those described in studies in more affluent
countries in temperate and subtropical areas of the world. Because
of unique co-morbidities in sub-Saharan Africa compared to other
areas of the world [27], more research is needed to characterize
shedding dynamics and impact on disease transmission for pH1N1
infection in African communities.
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